For example, in prostate and bladder cancer, NRBP1 expression is positively associated with poor clinical outcomes, and silencing of NRBP1 leads to decreased proliferation, and for the latter cancer, reduced xenograft growth [14, 16]. Here, NRBP1 is linked to cancer.